Adenocarcinoma: all 1,996 studies

Page 3 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingNCT06196697Phase 2
• Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRCNot yet recruitingNCT06195670Phase 1/2
• Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric AdenocarcinomaRecruitingNCT06192186Phase 4
• Prostatic Size Reduction Following of Leuprorelin AcetateRecruitingNCT06184464
• M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.RecruitingNCT06177041Phase 3
• Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaRecruitingNCT06163729Phase 2
• A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerRecruitingNCT06158919Not applicable
• Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics ApproachNot yet recruitingNCT06151691
• Anatomical-Clinical Base of Adenocarcinoma PancreaticRecruitingNCT06128343
• A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsRecruitingNCT06124963Phase 2
• SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingNCT06123494Phase 3
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2
• Most Total Pancreatectomies for Ductal Adenocarcinoma Can Be Replaced by Whipple Over the Splenic Artery: A Before and After StudyRecruitingNCT06119776
• Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 MutationsNot yet recruitingNCT06118658Phase 2
• Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors ResistanceNot yet recruitingNCT06118645Phase 2
• Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
• XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter StudyRecruitingNCT06091423Phase 2
• Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)Not yet recruitingNCT06090214Not applicable
• The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.RecruitingNCT06068023
• Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticRecruitingNCT06056115Not applicable
• Improving Pancreatic Cancer Care by the Use of Computational Science and TechnologyRecruitingNCT06055010
• Factors Affecting the Results of Treatment of Patients With Colorectal CancerRecruitingNCT06050447
• Early Access Program for ZolbetuximabAvailableNCT06048081
• Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.RecruitingNCT06046131Not applicable
• "Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational StudyNot yet recruitingNCT06044064
• A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerRecruitingNCT06038578Phase 2
• Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)RecruitingNCT06031181Phase 3
• Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albuminEnrolling by invitationNCT06030934Phase 2
• Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction CancerRecruitingNCT06028737Phase 2/3
• An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic AdenocarcinomaNot yet recruitingNCT06015321Phase 2
• A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal AdenocarcinomaRecruitingNCT05997147
• Neoadjuvant Toripalimab for dMMR/MSI-H Gastric CancerRecruitingNCT05994456Phase 2
• The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):Not yet recruitingNCT05986227Phase 1/2
• NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101RecruitingNCT05984810Phase 2
• Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05978050Phase 3
• Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric CancerNot yet recruitingNCT05974059Phase 2
• Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05970627Phase 2
• Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05960955Phase 2
• Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT05955157Phase 2/3
• Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal AdenocarcinomaRecruitingNCT05955092
• Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer CachexiaNot yet recruitingNCT05954117Not applicable
• To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Not yet recruitingNCT05948449Phase 2
• WSI Based DL for Diagnosing the IASLC Grading System of Lung AdenocarcinomaRecruitingNCT05925764
• SBRT With Focal Dose Escalation on DIL in Localized Prostate CancerRecruitingNCT05919524Not applicable
• Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Phase 3
• Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)RecruitingNCT05872685Phase 2
• PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
• Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal AdenocarcinomaRecruitingNCT05858567Phase 2
• Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of ResectabilityRecruitingNCT05853198Not applicable
• Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmRecruitingNCT05838053
• Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung AdenocarcinomaRecruitingNCT05830812
• The Role of Artificial Intelligence in Endoscopic Diagnosis of Esophagogastric Junctional Adenocarcinoma：A Single Center, Case-control, Diagnostic StudyNot yet recruitingNCT05819099
• Study of Comparing of With and Without Sequential Therapy of S-1RecruitingNCT05813015Phase 3
• Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With SindillimabNot yet recruitingNCT05810142
• Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)RecruitingNCT05794724
• Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)RecruitingNCT05794711
• Prognostic and Predictive Markers of Treatment Response in Patients With PAC.RecruitingNCT05776342
• Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable PrognosisEnrolling by invitationNCT05754788
• The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic CancerRecruitingNCT05752812
• Genetics of Appendix Cancer StudyRecruitingNCT05734430
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsRecruitingNCT05733000Phase 2
• Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05729646Phase 2
• Dose De-escalation in Prostate Radiotherapy Using the MRLRecruitingNCT05709496Not applicable
• Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based BiomarkersRecruitingNCT05688176
• Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Phase 2
• A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
• A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI StatusRecruitingNCT05669092Phase 3
• Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard TherapyNot yet recruitingNCT05649163
• Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
• Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic CancerNot yet recruitingNCT05611359Not applicable
• A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerRecruitingNCT05604560Phase 2
• A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Not yet recruitingNCT05594381Phase 2
• Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in HumansRecruitingNCT05591053Not applicable
• PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical CancerRecruitingNCT05581121Phase 3
• Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for CancerRecruitingNCT05574647Not applicable
• Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric AdenocarcinomaRecruitingNCT05563012Phase 2
• A Prospective Observation Registry Study on the Alimentary Reconstruction After Radical Proximal GastrectomyRecruitingNCT05539105
• 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic AdenocarcinomaNot yet recruitingNCT05531045
• A Single-arm Exploratory Study of Neoadjuvant TherapyRecruitingNCT05527808Not applicable
• Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05505461Phase 2
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingNCT05503667Phase 2
• AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
• XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Phase 2
• A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)RecruitingNCT05472259Phase 2
• Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyRecruitingNCT05469022Phase 2
• RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2RecruitingNCT05403242Phase 1/2
• Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid TumorsRecruitingNCT05393986Phase 1
• Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced GastricNot yet recruitingNCT05387681Phase 2
• A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction AdenocarcinomaRecruitingNCT05370144Not applicable
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
• Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic AdenocarcinomaRecruitingNCT05363007Phase 2
• Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric JunctionRecruitingNCT05356520Not applicable
• Survival, Quality of Life and Resectability in Locally Advanced Pancreatic CancerRecruitingNCT05356039
• Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate CancerRecruitingNCT05328505Not applicable
• Transcriptomic Signatures in Gastric AdenocarcinomaRecruitingNCT05319392
• PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric CancerRecruitingNCT05303714Phase 3
• Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric AdenocarcinomaNot yet recruitingNCT05270824Phase 3
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKRecruitingNCT05266846Phase 2
• Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical AdenocarcinomaNot yet recruitingNCT05259540Phase 2
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerRecruitingNCT05254171Phase 2/3

← Adenocarcinoma overview